Dr Elena Provenzano

CRUK Therapeutic Discovery Laboratories
Cambridge University Hospitals NHS Foundation Trust

University departments
Cancer Research UK Cambridge Institute
NHS or other affiliations
Breast Unit

Position: Clinical Consultant
Personal home page:

PubMed journal articles - click here

Research description

I am lead pathologist for several research projects in breast cancer. My primary interest is the translational aspect of clinical trials particularly in the neoadjuvant setting. Current trials include ARTemis, PARTNER, PRIMETIME and Neo-RT clinical trials in Addenbrooke’s Hospital. I am also local pathologist for the SEARCH and METABRIC studies. The latter is a multi centre collaborative study examining the molecular biology of the integrative clusters of breast cancer with a substudy specifically looking at precursor lesions.

Research Programme or Virtual Institute
Breast Cancer Virtual Institute
Methods and technologies
Clinical trials
Gene expression profiling
Tumour type interests
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Ali HR, Dariush A, Provenzano E, Bardwell H, Abraham JE, Iddawela M, Vallier AL, Hiller L, Dunn JA, Bowden SJ, Hickish T, McAdam K, Houston S, Irwin MJ, Pharoah PD, Brenton JD, Walton NA, Earl HM, Caldas C. Breast Cancer Res. 2016 Feb 16;18(1):21.
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Murtaza M, Dawson SJ, Pogrebniak K, Rueda OM, Provenzano E, Grant J, Chin SF, Tsui DW, Marass F, Gale D, Ali HR, Shah P, Contente-Cuomo T, Farahani H, Shumansky K, Kingsbury Z, Humphray S, Bentley D, Shah SP, Wallis M, Rosenfeld N, Caldas C. Nat Commun. 2015 Nov 4;6:8760.
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R. Sci Rep. 2016 Jan 5;6:18517.
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF. Mod Pathol. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? Earl H, Provenzano E, Abraham J, Dunn J, Vallier AL, Gounaris I, Hiller L. BMC Med. 2015 Sep 22;13(1):234. doi: 10.1186/s12916-015-0472-7.
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. Ali A, Provenzano E, Bartlett JM, Abraham J, Driver K, Munro AF, Twelves C, Poole CJ, Hiller L, Dunn J, Earl HM, Caldas C, Pharoah P. Int J Cancer. 2013 Mar 9.
A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Provenzano E, Vallier AL, Champ R, Walland K, Bowden S, Grier A, Fenwick N, Abraham J, Iddawela M, Caldas C, Hiller L, Dunn J, Earl HM. Br J Cancer. 2013 Mar 5;108(4):866-72.